RNAdjuvant(®), a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

Documenti analoghi

• A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines
  di: Kallen, Karl-Josef, et al.
  Pubblicazione: (2013)
• Self-adjuvanted RNActive(® )vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
  di: Kowalczyk, Aleksandra, et al.
  Pubblicazione: (2014)
• A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
  di: Koch, Sven D, et al.
  Pubblicazione: (2014)
• Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
  di: Kowalczyk, Aleksandra, et al.
  Pubblicazione: (2014)
• mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
  di: Fotin-Mleczek, Mariola, et al.
  Pubblicazione: (2014)